

## Conformation of cationic *N,N*-dimethylglycine in dimethylglycinium trifluoroacetate

V. H. Rodrigues, J. A. Paixão,\* M. M. R. R. Costa and  
A. Matos Beja

CEMDRX, Departamento de Física, Faculdade de Ciências e Tecnologia,  
Universidade de Coimbra, P-3004-516 Coimbra, Portugal  
Correspondence e-mail: jap@pollux.fis.uc.pt

Received 19 December 2000

Accepted 2 January 2001

In the title compound,  $C_4H_{10}NO_2^+ \cdot C_2F_3O_2^-$ , the main N—C—COOH skeleton of the protonated amino acid is nearly planar. The C=O/C—N and C=O/O—H bonds are *syn* and the two methyl groups are *gauche* to the methylene H atoms. The conformation of the cation in the crystal is compared to that given by *ab initio* calculations (Hartree–Fock, self-consistent field molecular-orbital theory). The trifluoroacetate anion has the typical staggered conformation with usual bond distances and angles. The cation and anion form dimers through a strong O—H $\cdots$ O hydrogen bond which are further interconnected in infinite zigzag chains running parallel to the *a* axis by N—H $\cdots$ O bonds. Weaker C—H $\cdots$ O interactions involving the methyl groups and the carboxy O atoms of the cation occur between the chains.

### Comment

*N,N*-Dimethylglycine [DMG; IUPAC name: 2-(*N,N*-dimethylamino)acetic acid] is a sweet-tasting substance legally considered as a nutrient and freely available in health-food stores. It is a popular ingredient of supplementary diet tablets and 'energetic drinks' for sportsmen. In living cells, DMG is present as a product of the metabolic pathways of choline and methionine. DMG has been used to improve situations of mental disturbance, like autism, seizures and aging, and of physical and athletic performance in humans and animals (*e.g.* racehorses), but the therapeutic value of DMG is still the subject of much controversy (Tonda & Hart, 1992; Kendall, 1994; Bolman & Richmond, 1999). Some studies claim that DMG can significantly enhance, at least temporarily, the immune system (Graber *et al.*, 1981; Reap & Lawson, 1990).

From a chemical point of view, DMG belongs to the family of *N*-methylated derivatives of glycine which also includes sarcosine (*N*-methylglycine) and betaine (*N,N,N*-trimethylglycine) as members (Meister, 1965). Compounds of the parent molecule, glycine, first attracted attention when ferroelectric behaviour was discovered in isomorphous triglycine sulfate (Matthias *et al.*, 1956), selenate and trifluoroberyllate

(Pepinsky *et al.*, 1957), and in diglycine nitrate (Pepinsky *et al.*, 1958). Later, several compounds of sarcosine and betaine were also found to have interesting physical properties, like ferroelastic (Zobetz & Preisinger, 1989), ferroelectric or antiferroelectric behaviour, often associated with structural phase transitions to commensurate or incommensurate superstructures (Pepinsky & Makita, 1962; Ashida *et al.*, 1972; Mishima *et al.*, 1984; Shildkamp & Spilker, 1984; Haussühl, 1984, 1988; Almeida *et al.*, 1992). Although an impressive number of structural studies on glycine, sarcosine and betaine compounds triggered by these discoveries has been reported, very few crystallographic studies of dimethylglycine compounds have been undertaken.

The DMG molecule has an amphoteric character and can exist in an anionic or a cationic form, as well as in the two uncharged tautomeric forms, one of which, with neutral amino and carboxylic acid groups, is thought to be the more stable form in the gas phase; in the dipolar zwitterionic form, stable in aqueous solution, the molecule has a positively charged dimethylammonium group and a negatively charged carboxylate group. When the molecule acts as an acid, an H atom is released from the former group, forming the dimethylglycinate anion. The cation is formed when the molecule acts as a base by accepting a proton at the negatively charged carboxylate group of the zwitterion. Due to this amphoteric character, a large number of DMG salts and adducts can be formed. In the anionic form, it is known that DMG is a good complexation agent of *p*- and *d*-metals, a property that is shared with the parent molecule (glycine), sarcosine and betaine. Chelation occurs commonly *via* the carboxylate group, but metal binding to the N atom may also occur (Darensbourg *et al.*, 1994). According to a recent survey of the Cambridge Structural Database (October 2000 release; Allen & Kennard, 1993), there is only one reported crystal structure where DMG is in the cationic form, that of dimethylglycinium chloride (Santarsiero & Marsh, 1983). The crystal structure of pure DMG itself has not yet been reported, which is certainly due to the fact that the pure substance is highly hygroscopic and deliquescent, a property common to several salts of DMG with organic acids. Recently, a theoretical *ab initio* study of the molecular conformations of DMG and sarcosine has been carried out by Headley & Starnes (1996). It was found that the molecule has some conformational flexibility, due to the rotational freedom of the 'rigid' dimethylammonium and carboxylate groups around the N—C and C—C bonds, respectively, and of the hydroxyl group around the C—O bond. For DMG, Headley & Starnes identified five distinct stable conformers.


We are presently engaged in a systematic study of the structural and dielectric properties of simple salts and adducts of *N*-methylated amino acids in order to find other compounds with ferro- or antiferroelectric order which might possibly induce structural phase transitions at low temperature. By varying the acid strength of the counter-ion, we aim at getting a deeper understanding of the role of the intermolecular interactions, in particular of the different patterns of hydrogen bonding between the anion and the cation *via* the carboxy and



found in other structures (Nahringbauer *et al.*, 1979), with an average C–F bond length and F–C–F angle of 1.323 (1) Å and 106.4 (3)°, respectively. The average F–C–C angle is 112 (1)°. The carboxylate group of the anion is planar within 0.0144 (19) Å; the C5–C6 bond length [1.530 (3) Å] is longer than the average  $Csp^3$ – $Csp^2$  bond, but is within the normal range of values found in trifluoroacetic acid and trifluoroacetate compounds (Lundgren, 1976).


The cation and anion interact directly *via* a strong hydrogen bond between their carboxylic acid groups [O1···O4<sup>i</sup> 2.593 (2) Å; symmetry code: (i)  $\frac{1}{2} + x, \frac{3}{2} - y, 1 - z$ ]. These dimers are interconnected in zigzag chains running parallel to the *a* axis *via* a moderately strong hydrogen bond between the amino N–H group and the carboxy O4 atom of the anion [N···O 2.836 (2) Å]. Parallel chains are further linked by weaker C–H···O interactions involving the methyl groups and the carboxy O atoms of the amino acid cation, as depicted in Fig. 2. It is remarkable that the two bare O atoms of the anion have such a distinct role in hydrogen bonding; O4 acts twice as an acceptor, whereas atom O3 does not participate in any hydrogen bond. Also, no hydrogen bonds can be ascribed to the F atoms, which seem to have a passive role in the network of intermolecular interactions. However, this is not an exceptional occurrence. A recent statistical survey of the Cambridge Structural Database (Allen & Kennard, 1993) has shown that the neutral F atom exhibits an anomalously small number of short contacts with strong hydrogen donors, such as the O–H and N–H groups, in contrast with the much larger number of contacts found for the F<sup>−</sup> anion (Dunitz & Taylor, 1997). The notable exceptions are F··· $\pi$  interactions, for which a statistically significant number of short contacts with appropriate directional characteristics was disclosed (Prasanna & Guru Row, 2000).

It should be pointed out that the atomic displacement tensors of the F atoms have an enhanced anisotropic character which might indicate a slight disorder, probably of a dynamic nature, of these atoms. It is plausible that at room temperature, the CF<sub>3</sub> groups rotate, undergoing small angular oscillations around the single C–C bond, particularly taking into



**Figure 1**  
ORTEPII (Johnson, 1976) plot of the title compound. Displacement ellipsoids are drawn at the 50% probability level.

account that the F atoms do not engage in hydrogen bonding with neighbouring molecules. The more anisotropic character of the atomic displacement tensor of the O3 atom compared with that of O4 may also reflect the fact that the former atom does not participate in the hydrogen-bond network.



**Figure 2**  
Projection of the title structure along the *b* axis showing the hydrogen-bonded chains.

## Experimental

Small colourless crystals of block form were obtained after several weeks evaporation of the solution obtained from adding an excess of trifluoroacetic acid (Aldrich, 99%) directly to 1 g of pure dimethylglycine, as purchased from Aldrich (98%). A small single crystal was enclosed in a sealed glass capillary and checked prior to data collection by photographic methods.

### Crystal data

$C_4H_{10}NO_2^+ \cdot C_2F_3O_2^-$   
 $M_r = 217.15$   
Orthorhombic, *Pbca*  
 $a = 10.4286$  (5) Å  
 $b = 12.1213$  (12) Å  
 $c = 14.6271$  (18) Å  
 $V = 1849.0$  (3) Å<sup>3</sup>  
 $Z = 8$   
 $D_x = 1.560$  Mg m<sup>−3</sup>

Mo  $K\alpha$  radiation  
Cell parameters from 25 reflections  
 $\theta = 7.60$ – $15.18^\circ$   
 $\mu = 0.164$  mm<sup>−1</sup>  
 $T = 293$  (2) K  
Block, colourless  
 $0.36 \times 0.28 \times 0.26$  mm

### Data collection

Enraf–Nonius CAD-4 diffractometer  
Profile data from  $\omega$ – $2\theta$  scans  
2039 measured reflections  
1631 independent reflections  
1313 reflections with  $I > 2\sigma(I)$   
 $R_{int} = 0.026$

$\theta_{max} = 25.03^\circ$   
 $h = 0 \rightarrow 12$   
 $k = 0 \rightarrow 14$   
 $l = -17 \rightarrow 17$   
3 standard reflections  
frequency: 180 min  
intensity decay: 6%

Refinement

Refinement on  $F^2$   
 $R[F^2 > 2\sigma(F^2)] = 0.037$   
 $wR(F^2) = 0.105$   
 $S = 1.038$   
 1631 reflections  
 158 parameters  
 Only coordinates of H atoms refined

$w = 1/[\sigma^2(F_o^2) + (0.0432P)^2 + 1.2200P]$   
 where  $P = (F_o^2 + 2F_c^2)/3$   
 $(\Delta/\sigma)_{\max} < 0.001$   
 $\Delta\rho_{\max} = 0.32 \text{ e } \text{\AA}^{-3}$   
 $\Delta\rho_{\min} = -0.22 \text{ e } \text{\AA}^{-3}$   
 Extinction correction: *SHELXL97*  
 Extinction coefficient: 0.0037 (8)

**Table 1**  
 Selected geometric parameters (Å, °).

C1—O2	1.198 (2)	C5—C6	1.530 (3)
C1—O1	1.301 (2)		
O2—C1—C2—N	−3.2 (3)	C1—C2—N—C3	−73.7 (2)
O1—C1—C2—N	178.09 (16)	C1—C2—N—C4	161.49 (19)

**Table 2**  
 Hydrogen-bonding geometry (Å, °).

<i>D</i> —H··· <i>A</i>	<i>D</i> —H	H··· <i>A</i>	<i>D</i> ··· <i>A</i>	<i>D</i> —H··· <i>A</i>
O1—H1···O4 <sup>i</sup>	0.89 (3)	1.71 (3)	2.593 (2)	175 (3)
N—H4···O4	0.84 (2)	2.04 (2)	2.836 (2)	158 (2)
C3—H5···O2 <sup>ii</sup>	0.96 (3)	2.37 (3)	3.302 (3)	163 (2)
C3—H7···O1 <sup>iii</sup>	0.97 (3)	2.52 (3)	3.470 (3)	166 (2)

Symmetry codes: (i)  $\frac{1}{2} + x, \frac{3}{2} - y, 1 - z$ ; (ii)  $x - \frac{1}{2}, \frac{3}{2} - y, 1 - z$ ; (iii)  $x - \frac{1}{2}, y, \frac{1}{2} - z$ .

All H atoms were located on a difference Fourier map and were refined isotropically [C—H = 0.96 (3)–0.97 (3) Å], with  $U_{\text{iso}}$  values constrained to that of the parent atom using *SHELXL* defaults. Examination of the crystal structure with *PLATON* (Spek, 1995) showed that there are no solvent-accessible voids in the crystal lattice.

Data collection: *CAD-4 Software* (Enraf–Nonius, 1989); cell refinement: *CAD-4 Software*; data reduction: *PLATON* (Spek, 1995); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEPII* (Johnson, 1976); software used to prepare material for publication: *SHELXL97*.

This work was supported by Fundação para a Ciência e a Tecnologia (FCT) and FEDER under project SAPIENS-POCTI/33495/QUI/00.

Supplementary data for this paper are available from the IUCr electronic archives (Reference: SK1450). Services for accessing these data are described at the back of the journal.

References

Allen, F. H. & Kennard, O. (1993). *Chem. Des. Autom. News*, **8**, 1, 31–37.  
 Almeida, A., Chaves, M. R., Kiat, J. M., Schneck, J., Schwartz, W., Toledano, J. C., Ribeiro, J. L., Klopperpieper, A., Muser, H. E. & Albers, J. (1992). *Phys. Rev. B*, **45**, 9576–9582.  
 Ashida, T., Bando, S. & Kakudo, M. (1972). *Acta Cryst.* **B28**, 1560–1565.  
 Bolman, W. M. & Richmond, J. A. (1999). *J. Autism Dev. Disord.* **29**, 191–194.  
 Darensbourg, D. J., Atnip, E. V., Klausmeyer, K. K. & Reibenspies, J. H. (1994). *Inorg. Chem.* **33**, 5230–5237.  
 Dunitz, J. D. & Taylor, R. (1997). *Chem. Eur. J.* **3**, 89–98.  
 Enraf–Nonius (1989). *CAD-4 Software*. Version 5.0. Enraf–Nonius, Delft, The Netherlands.  
 Graber, C. D., Goust, J. M., Glassman, A. D., Kendall, R. & Loadholt, C. B. (1981). *J. Infect. Dis.* **143**, 101–105.  
 Haussühl, S. (1984). *Solid State Commun.* **50**, 63–65.  
 Haussühl, S. (1988). *Solid State Commun.* **68**, 963–966.  
 Headley, A. D. & Starnes, S. D. (1996). *J. Mol. Struct. (Theochem)*, **370**, 147–155.  
 Johnson, C. K. (1976). *ORTEPII*. Report ORNL-5138. Oak Ridge National Laboratory, Tennessee, USA.  
 Kendall, R. V. (1994). *Ann. Pharmacother.* **28**, 973.  
 Lundgren, J.-O. (1976). *Acta Cryst.* **B34**, 2432–2435.  
 Matthias, B. T., Miller, C. E. & Remeika, J. P. (1956). *Phys. Rev. B*, **104**, 849–885.  
 Meister, A. (1965). In *Biochemistry of the Amino Acids*, 2nd ed. New York: Academic Press.  
 Mishima, N., Itoh, K. & Nakamura, E. (1984). *Acta Cryst.* **C40**, 1824–1827.  
 Mootz, D. & Schilling, M. (1992). *J. Am. Chem. Soc.* **114**, 7435–7439.  
 Nahrungbauer, I., Lundgreen, J.-O. & Andersen, E. K. (1979). *Acta Cryst.* **B35**, 508–510.  
 Pepinsky, R. & Makita, Y. (1962). *Bull. Am. Phys. Soc. Ser. II*, **7**, 241.  
 Pepinsky, R., Okaya, Y. & Jona, F. (1957). *Bull. Am. Phys. Soc. Ser. II*, **4**, 220.  
 Pepinsky, R., Vedam, K., Hoshino, S. & Okaya, Y. (1958). *Phys. Rev.* **111**, 430–432.  
 Prasanna, M. D. & Guru Row, T. N. (2000). *Cryst. Eng.* **3**, 135–154.  
 Reap, E. A. & Lawson, J. W. (1990). *J. Lab. Clin. Med.* **115**, 481–486.  
 Rodrigues, V. H., Paixão, J. A., Costa, M. M. R. R. & Matos Beja, A. M. (2000). *Acta Cryst.* **C56**, 1053–1055.  
 Santarsiero, B. D. & Marsh, R. E. (1983). *J. Crystallogr. Spectrosc. Res.* **13**, 245–252.  
 Schmidt, M. W., Baldrige, K. K., Boatz, J. A., Elbert, S. T., Gordon, M. S., Jensen, J. J., Koseki, S., Matsunaga, N., Nguyen, K. A., Su, S., Windus, T. L., Dupuis, M. & Montgomery, J. A. (1993). *J. Comput. Chem.* **14**, 1347–1363.  
 Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.  
 Schildkamp, W. & Spilker, J. (1984). *Z. Kristallogr.* **168**, 159–171.  
 Spek, A. L. (1995). *PLATON*. University of Utrecht, The Netherlands.  
 Strehlow, H. & Hildebrandt, P. (1990). *Ber. Bunsenges. Phys. Chem.* **94**, 173–179.  
 Tonda, M. E. & Hart, L. L. (1992). *Ann. Pharmacother.* **26**, 935–937.  
 Zobetz, E. & Preisinger, A. (1989). *Monatsh. Chem.* **120**, 291–298.